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E-mail: joetbruder@gmail.comT cells are critical effectors of host immunity that target intra-
cellular pathogens, such as the causative agents of HIV, tuber-
culosis, and malaria. The development of vaccines that induce
effective cell-mediated immunity against such pathogens has
proved challenging; for tuberculosis and malaria, many of the
antigens targeted by protective T cells are not known. Here,
we report a novel approach for screening large numbers of
antigens as potential targets of T cells. Malaria provides an
excellent model to test this antigen discovery platform because
T cells are critical mediators of protection following immuniza-
tion with live sporozoite vaccines and the specific antigen
targets are unknown. We generated an adenovirus array by
cloning 312 highly expressed pre-erythrocytic Plasmodium
yoelii antigens into adenovirus vectors using high-throughput
methodologies. The array was screened to identify antigen-spe-
cific CD8+ T cells induced by a live sporozoite vaccine regimen
known to provide high levels of sterile protection mediated by
CD8+ T cells. We identified 69 antigens that were targeted by
CD8+ T cells induced by this vaccine regimen. The antigen
that recalled the highest frequency of CD8+ T cells, PY02605,
induced protective responses in mice, demonstrating proof of
principle for this approach in identifying antigens for vaccine
development.
INTRODUCTION
Almost all licensed vaccines are thought to mediate protection
through antibody production; therefore, antigen discovery research
and development has focused largely on the identification of anti-
gens that induce protective antibodies.1 The availability of serum,
the ease of working with antibodies, and, more recently, advances
in microarray technology have facilitated these efforts. However,
vaccine development for some of the most devastating infectious
diseases, such as malaria, tuberculosis (TB), and HIV, has met
with limited success, partially because these organisms have intra-
cellular life cycle stages that are not targeted by antibodies, and
they have developed sophisticated mechanisms to avoid clearance
by host immune responses.2 Since T cells have been implicated in
protection from these diseases,3–7 considerable efforts have been20 Molecular Therapy: Methods & Clinical Development Vol. 7 Decemb
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sponses. However, for infectious agents with large genomes that
express many potential T cell antigens such as parasites and bacte-
ria, many of the specific antigens that are targeted by protective
CD8+ T cells are not known. Identification of the target antigens
of protective T cell responses would greatly facilitate vaccine
development.
Malaria killed approximately 429,000 people in 2015,8 most of them
children, in sub-Saharan Africa. Despite decades of effort, a highly
effective malaria vaccine is not available. Immunization with attenu-
ated Plasmodium sporozoites can provide high levels of protection in
mice, non-human primates, and humans.9–12 Protection is mediated
by CD8+ T cells, which target a set of mostly unknown pre-erythro-
cytic stage antigens.13–18 Activated CD8+ T cells can kill infected
hepatocytes, thereby preventing blood-stage infection, which is
responsible for the clinical symptoms of the disease. However, sub-
stantial delivery issues are a considerable barrier to licensure of live
sporozoite-based vaccines, and broad protection against circulating
strains has not been demonstrated. An alternative approach is to
identify the targets of these protective CD8+ T cell responses and
formulate them into a multivalent subunit vaccine designed to induce
sustained T cell immunity.
The two P. falciparum sporozoite vaccines that are associated with
high levels of protection in humans are radiation-attenuated sporo-
zoites (RAS) and live sporozoites with concomitant chloroquine
treatment to kill newly emerging blood-stage parasites (SPZ+CQ).er 2017 ª 2017 GenVec, Inc.
ecommons.org/licenses/by/4.0/).
Figure 1. Schematic View of High-Throughput Ad-Array Generation and
Antigen Identification Assays
The general steps involved in generating a defined array of adenovectors and their
use in antigen discovery screens using high-throughput technology are indicated.
www.moleculartherapy.orgImmunization with RAS leads to infection of hepatocytes and
expression of a set of early liver-stage genes, but these attenuated
sporozoites do not develop into late liver and blood stages.19 In
BALB/c mice, the protective T cell response following vaccination
with RAS is dominated by CD8+ T cells specific for the major sur-
face protein on the sporozoite, the circumsporozoite protein
(CSP), although T cell responses specific for other antigens can
also contribute to protection.20 In humans, T cell responses specific
for several antigens have been observed following RAS immuniza-
tion.21–23 In contrast to RAS, vaccination with SPZ+CQ allows
expression of the full repertoire of liver-stage genes and replication
of the parasite in hepatocytes.24 Unlike RAS, where protection re-
quires approximately 1,000 bites from infected mosquitoes, SPZ+CQ
can provide durable protection in volunteers with as few as 30–45
bites.25 This robust protection is strictly dependent on CD8+
T cells26 and immune response to CSP is not required, highlighting
the fact that the specific antigen targets of protective immunity are
not known.27
In this report, we describe a novel platform for the discovery of anti-
gens that are the targets of T cell responses to infection (Figure 1).
Using this system, we identified 69 pre-erythrocytic antigens that
were targeted by CD8+ T cell responses in mice immunized with pro-
tective regimens of P. yoelii SPZ+CQ. Moreover, we demonstrated
that the antigen that recalled the highest frequency of interferon
gamma (IFNg)-expressing CD8+ T cells, PY02605, provided sterile
protection in mice when delivered in a DNA prime-adenovector
boost regimen.Molecular TRESULTS
Generation of an Array of Adenovectors That Express a Panel of
Highly Expressed P. yoelii Pre-erythrocytic Antigens
Pre-erythrocytic antigens, which are expressed in the sporozoite and
liver stages of the Plasmodium spp. life cycle, are particularly prom-
ising targets for malaria vaccine development, with great potential
to prevent infection and transmission.28 The pre-erythrocytic stages
of the parasitic life cycle are vulnerable to vaccine intervention
because their antigens are expressed at a time when low numbers of
sporozoites are transmitted by the mosquito to the human host and
only a few hepatocytes become infected. We selected P. yoelii pre-
erythrocytic genes with identifiable P. falciparum orthologs for gener-
ation of an adenovector array (Ad-array) based on their level of
expression in microarray29–31 and protein mass spectrometry29 data-
sets. Gene selection was made without regard to protein function or
subcellular localization. In total, 312 P. yoelii genes were amplified
from genomic DNA and cloned into E1/E3-deleted adenovirus type
5 (Ad5) vector genomes (Figure 2).
To facilitate high-throughput production of the Ad-array, we
compared the efficiency of adenovector generation in multi-well
plates of different sizes. The adenovector plasmid had to convert
into an adenovirus vector in sufficient quantities and quality to func-
tion in the antigen screening assay. Initially, we tested conversions of
two pAdFlex plasmids that expressed the P. yoelii Hep17 antigen
(AdgHep17) and the cytomegalovirus p65 antigen (AdgCMVp65).
These large plasmids were transfected into 293 cells in 60-mm,
6-well, 12-well, 24-well, 48-well, and 96-well plates, and the cells
were passaged to increase the adenovector titer. We observed efficient
adenovector conversion in all of the wells as indicated by full cyto-
pathic effect (CPE) at passage 2. Vector identity was verified by
PCR using oligonucleotides that spanned the expression cassette (Fig-
ure 2B). Vector titers from each of the CPE wells (Table S1) demon-
strated equivalent yields per infected cell. These results indicated that
multiple adenovectors can be generated from pAdFlex adenovector
plasmids in a parallel process in multi-well plates and that 96-well
plates were suitable for the generation of the Ad-array.The Screening System
The overall design of our antigen screening system is shown in Fig-
ure 3A. To test the elements of the screen, we first determined the
MOI necessary to efficiently infect A20 cells. Cells were infected
with various doses of AdGFP, an Ad5 vector expressing GFP, and
the percentage of infected cells was measured 48 hr post-infection
(Figure 3B). MOIs of 10, 100, or 1,000 focal forming units (ffus)/
cell were required to infect approximately 2%, 10%, or 50% of the
cells, respectively. To determine if adenovirus vectors could efficiently
present antigen following infection of antigen presenting cells
(APCs), we immunized BALB/c mice with a PyCSP-expressing
plasmid, stimulated splenocytes from these mice with APCs infected
with an Ad5 vector expressing PyCSP (AdPyCSP), andmeasured acti-
vated T cells by the enzyme linked immunosorbent spot (ELISpot)
assay. We observed strong recall responses to the AdPyCSP-infectedherapy: Methods & Clinical Development Vol. 7 December 2017 21
Figure 2. Generating the Ad-Array
(A) >300 P. yoelii pre-erythrocytic genes were amplified
using P. yoelii genomic DNA and gene-specific primers.
PCR products were electrophoresed on 1% agarose gels,
showing a subset of 24 genes. The control is a pair of
oligonucleotide primers used to amplify the E1 region of
Ad5 DNA. (B) Parallel generation of two Ad-array vectors
in multi-well plates. The schematic indicates two Ad-array
vectors, AdgPyHep17 and AdgCMVp65. The inverted
terminal repeats (ITRs), CMV promoter, SV40 poly(A), and
the 25-bp-long attB recombinase sequences that flank
the transgene (B1 and B2) are indicated. Two plasmids,
encoding PyHep17 and CMVp65, were AdFlex linearized
with Pac I and transfected into 293 cells in 60-mm, 6-well,
12-well, 24-well, 48-well, and 96-well plates. Following
two passages in 293 cells in the same plate size, CPE was
observed in all wells. Viral DNA was obtained, and PCR
analysis was performed using primers that flank the
expression cassette as indicated by the arrows in the
schematic. The products of the PCR reaction were loaded
into a 1% agarose gel and electrophoresed. Arrows next
to AdgPyHep17 and AdgCMVp65 indicate the expected
size for the PCR products.
Molecular Therapy: Methods & Clinical Developmentcells, even at a low MOI, comparable to those generated by pulsing
APCs with a peptide containing the PyCSP immunodominant
epitope (Figure 3C). Very low responses were seen in the negative
controls. These results demonstrate that A20 cells (which express
both major histocompatibility complex [MHC] class I and class II
alleles) infected with AdPyCSP are able to present antigen to immune
T cells. This process was highly efficient, as strong T cell responses
were observed even at an MOI of 10, a multiplicity that resulted in
transduction of approximately 2% of the target cells. Increasing the
MOI resulted in substantially increased A20 cell transduction22 Molecular Therapy: Methods & Clinical Development Vol. 7 December 2017(Figure 3B) but only marginally increased func-
tional activity in the ELISpot assay (Figure 3C).
Thus, low-level target cell transduction is suffi-
cient for optimal activity to detect T cell re-
sponses in the ELISpot assay.
To determine whether lower-frequency T cell
responses from mice immunized with sporo-
zoite vaccines could be identified using our
approach, we assayed CD8+ T cell responses
specific for PyCSP from mice immunized with
protective regimens of RAS and SPZ+CQ. We
chose PyCSP as the test antigen because it is
the most well-characterized target of T cell re-
sponses from mice immunized with these regi-
mens.20,27 First, we assayed splenocytes from
mice immunized with a highly protective
three-dose regimen of RAS for the presence of
PyCSP-specific T cells. We were able to recall
PyCSP-specific T cells in splenocytes from these
mice using AdPyCSP-infected A20 cells in bothELISpot (Figure 4A) and intracellular cytokine staining (ICS) assays
(Figure 4B). Low background responses were observed in the negative
controls.
It was important to assess the degree of purity of the adenovector
preparation necessary for the screen because if unpurified adenovec-
tors were suitable, this would greatly simplify generation of the
Ad-array. Accordingly, we compared highly purified AdPyCSP (puri-
fied over three successive CsCl gradients) with cell lysates containing
unpurified recombinant adenovector. PyCSP-specific CD8+ T cell
Figure 3. Adenovector-Expressed Antigen Is Effective at Recalling T Cell
Responses from Immunized Mice
(A) Schema for in vitro antigen discovery. First, A20 APCs are infected with each
adenovector in the array. After 24 hr, the specific antigen of interest is expressed
and presented on MHC class I molecules. The infected APCs are incubated with
splenocytes isolated from immune animals to identify CD8+ T cells with specificity for
the antigens expressed in the Ad-array. These antigen-specific CD8+ T cells are
identified by either ICS and flow cytometry or ELISpot assays measuring IFNg
secretion. (B) Ad5 vector effectively transduces APCs. A20 cells were infected with
AdGFP at the indicated MOI. The percentage of GFP+ cells was determined by flow
cytometry. (C) AdPyCSP-infected APCs can recall CD8+ T cell responses from
www.moleculartherapy.org
Molecular Tresponses were detected with both purified and unpurified vectors
using ELISpot (Figure 4A) and ICS (Figure 4B) assays. Our results
indicated that vector purification is not required to identify antigens
that recall CD8+ T cell responses in mice immunized with RAS.
Ad-array vectors contain 25bp-long attB sequences flanking the
transgene (Figure 2B), which are remnants of the recombinase clon-
ing reaction.We compared Ad-array vectors directly with our vaccine
adenovectors, which do not carry the flanking attB sequences. Our
results indicate that the attB sequences did not inhibit the capacity
to recall T cell responses in mice (Figure 4C), indicating that Ad-array
vectors are suitable for screening.
Mice immunized with a two-dose regimen of 200, 2,000, and 20,000
SPZ+CQ were completely protected from P. yoelii sporozoite chal-
lenge (Figure 4D). Figure 4E shows that PyCSP-specific T cells were
induced by immunizing mice with a highly protective 2,000 SPZ+CQ
regimen. Splenocytes from immunized mice had a high background
of activated CD8+ T cells. When incubated with A20 cells infected
with the negative control vectors AdNull and AdGFP, 0.8%–0.9%
of the CD8+ T cells were activated. A20 cells infected with AdPyCSP
recalled PyCSP-specific T cell responses that were more frequent than
the negative controls. Statistically significant results were observed
with MOIs of 10 and 100 ffu/cell. These data suggested that it would
be possible to utilize our Ad-array technology to identify new antigen
targets of protective T cell responses following immunization of mice
with SPZ+CQ.
Identification of the Antigen Targets of CD8+ T Cells Induced
following Vaccination with Protective Regimens of SPZ+CQ
To generate protective T cells for the identification of antigens, we
used the 2,000 SPZ+CQ regimen and harvested splenocytes 2 weeks
after the last sporozoite immunization. The full array was screened
simultaneously, in triplicate, against these freshly isolated splenocytes
by ICS to identify pre-erythrocytic stage antigens able to recall
IFNg-expressing CD8+ T cells. A20 cells infected with 100 ffu/cell
AdgPyCSP were included as a positive control. Negative controls
included uninfected A20 cells and A20 cells infected with
100 ffu/cell of AdNull and AdGFP vectors. The mean of the negative
controls was 1% IFNg-expressing CD8+ T cells (Figure 5).We defined
antigens with responses greater than 2 SD of the mean of the negative
controls (>1.2% CD8+ IFNg+ cells) as positive hits in our screen. By
this definition, 69 of the antigens in the array were positive and
were targeted by CD8+ T cells induced in mice immunized with
SPZ+CQ (Figure 5; Table 1). Thirteen of these antigens recalledimmune mice. Target A20 cells were infected with various MOIs of an Ad5 vector
expressing PyCSP (AdPyCSP). Control targets were uninfected A20 cells, A20 cells
infected with various MOIs of an Ad5 vector that does not express a transgene
(AdNull), and A20 cells stimulated with an immunodominant PyCSP peptide (amino
acids 280–288, SYVPSAEQI). These targets were used to stimulate splenocytes
from BALB/c mice immunized with a PyCSP DNA vaccine. IFNg-expressing cells
were measured by ELISpot. SFC (spot-forming cells); error bars indicate the SEM
(n = 3). SFC, spot-forming cell.
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Figure 4. Adenovector-Expressed Antigen Is
Effective at Recalling CD8+ T Cell Responses from
Mice Immunized with Protective Regimens of
Sporozoite Vaccines
Target A20 cells were infected at the indicated MOIs with
AdPyCSP (either triple CsCl2 purified adenovector or
unpurified cell lysate from adenovector infected cells) and
incubated with splenocytes from RAS or SPZ+CQ-
immunized mice. Control targets were A20 cells infected
with AdNull, AdGFP, and uninfected A20 cells. (A) IFNg-
secreting cells from mice immunized with RAS were
measured by ELISpot. (B) CD8+ IFNg+ cells from mice
immunized with RAS were measured by ICS and flow
cytometry. (C) Comparison of Ad-array PyCSP vector
(AdgPyCSP) with AdPyCSP, which does not contain the
recombination motifs flanking the expression cassette.
CD8+ IFNg+ cells from mice immunized with RAS were
measured by ICS and flow cytometry. (D) Dose-response
analysis for efficacy of SPZ+CQ vaccine regimen following
immunization with 0, 200, 2,000, or 20,000 P. yoelii spo-
rozoites with chloroquine treatment. Mice were assessed
for sterile protection by blood smear. (E) AdPyCSP-in-
fected cells can recall CD8+ T cell responses from mice
immunized with 2,000 SPZ+CQ. Target A20 cells were
infected with cell lysates containing the indicated Ad5
vectors and antigen-specific CD8+ T cell responses were
measured by ICS and flow cytometry. Error bars indicate
the SEM (n = 3). Asterisks indicate statistically significant
differences compared with AdGFP (A), A20 (B and C), or
AdNull (E) controls (p < 0.05 by ANOVAwith the Bonferroni
mean-comparisons test).
Molecular Therapy: Methods & Clinical Developmenthigher-frequency CD8+ T cell responses than PyCSP. The antigen
that recalled the highest response was PY02605. We also analyzed
CD4+ T cell responses and tumor necrosis factor (TNF)-a and inter-
leukin (IL)-2 cytokines by ICS. CD4+ T cell responses were not
observed in this system. CD8+ TNF-a-expressing T cells were
observed and tended to mirror the CD8+ IFNg responses. Very low
levels of IL-2-expressing cells were observed (data not shown).
PY02605 Is a Protective Antigen
Since the SPZ+CQ regimen induces protective T cell responses
directed against antigens expressed in the pre-erythrocytic stages
of the parasite life cycle,26,27,32 we hypothesized that a subset of
antigens identified in the SPZ+CQ screen would induce protective
immune responses when delivered using a potent vaccine regimen
designed to optimize CD8+ T cell responses. Accordingly, we
compared antigens that ranked at the two extremes of our screening24 Molecular Therapy: Methods & Clinical Development Vol. 7 December 2017strategy, PY02605 and PY05837, for their ca-
pacity to protect mice against a sporozoite chal-
lenge. PY02605 recalled the highest frequency
of CD8+ T cells and PY05837 did not recall
antigen-specific T cell responses in our screen.
We tested the protective capacity of these anti-
gens using a DNA prime-Ad5 boost regimen in
BALB/c mice.33 Mice were immunized with100 mg of DNA vector expressing the specific antigen and then
boosted 6 weeks later with 1  1010 particle units (PUs) of an
Ad5 vector expressing the same antigen. Two weeks after the Ad5
boost, mice were challenged with P. yoelii sporozoites and protection
was monitored by microscopic examination of Giemsa-stained
blood smears. 43% of the PY02605 immunized mice were sterilely
protected (6 of 14 mice), indicating that PY02605 can provide
protection in mice (Table 2). Only 1 mouse from the group of 14
immunized with the PY05837 antigen was negative for blood-stage
parasitemia following challenge, suggesting that this antigen is not
protective. The positive control group, which was immunized with
PyCSP-expressing DNA and Ad5 vectors, protected 100% of the
mice. The negative control group, immunized with DNA and Ad5
vectors that did not express any transgene (Null) did not protect
any mice (Table 2). These data indicate that our antigen discovery
system is capable of identifying protective antigens.
Figure 5. Identification of Targets of CD8+ T Cell Responses Induced by
a Highly Protective SPZ+CQ Vaccine Regimen
Splenocytes from BALB/c mice immunized with SPZ+CQ were screened for CD8+
recall responses stimulated by 312 pre-erythrocytic antigens and evaluated by ICS
and flow cytometry. The mean of the negative controls is indicated by the horizontal
green line. The dotted green line indicates responses that are R2 SD above the
mean of the negative controls. Arrows indicate two antigens tested for protection
shown in Table 2.
www.moleculartherapy.orgPF3D7_0932900 Is Immunogenic in Mice
To begin evaluation of a selected pre-erythrocytic antigen as a vaccine
candidate, we cloned the P. falciparum ortholog of PY02605 into a
highly immunogenic and low seroprevalent gorilla adenovector
(GC46)34,35 and tested immunogenicity in mice. PF3D7_0932900
was codon optimized for expression in mammals, synthesized, and
used to produce GC46.PF3D7_0932900. We immunized BALB/c
mice (n = 6/group) with a single intramuscular (IM) administration
of GC46.PF3D7_0932900 (1  109 PU). GC46.Null immunized and
naive mice were included as control groups. At 21 days post-immu-
nization, mice were euthanized for T cell studies. Antigen-specific
T cell responses were measured from splenocytes by flow cytometry
after stimulation with overlapping peptide pools and staining for
cytokines and cell surface markers (Figure 6). GC46.PF3D7_0932900
was highly immunogenic, inducing robust antigen-specific CD8+ and
low-level CD4+ T cell responses.
DISCUSSION
Identification of CD8+ T cell targets of infectious disease has the
potential to increase our understanding of cellular immunity and to
facilitate the development of vaccines, diagnostics, and therapeutics.
In this report, we describe a novel antigen discovery system and
demonstrate its capacity to identify the antigen targets of protective
T cell responses to infection. Although we demonstrated the feasi-
bility of this system for malaria, we expect that the Ad-array technol-
ogy and screens similar to the one employed here may also be useful
for identifying the antigens targeted by T cell responses to other infec-
tious agents or associated with other disease states. Arrayed adeno-
viral expression libraries have been produced previously and used
to identify gene products involved in disease pathways36; however,Molecular Tto our knowledge, this work is the first demonstration of the use of
Ad-array technology to identify the antigen targets of cellular immu-
nity. We show that low titers of unpurified adenovirus vector, quan-
tities that transduce only 2% of autologous APCs, are sufficient to
recall antigen-specific T cell responses inmice immunized with highly
protective regimens of live sporozoite vaccines. Our ability to use low
quantities of unpurified vector in the antigen discovery screen
simplifies high-throughput Ad-array production and indicates poten-
tial for producing large Ad-arrays encoding the full transcriptome of
complex pathogens with large genomes.
Advantages of the Ad-array technology over other T cell antigen
discovery efforts are that adenoviruses efficiently infect many cell
types including APCs37 and that, following infection, full-length pro-
teins are expressed and multiple undefined epitopes are presented,
similar to what occurs during a natural infection. The Ad-array tech-
nology was as effective as the immunodominant PyCSP peptide in
detecting PyCSP-specific CD8+ T cell responses. Moreover, this tech-
nology was highly sensitive, detecting low-level PyCSP-specific CD8+
T cell responses following immunization with RAS and SPZ+CQ.
Other T cell antigen discovery efforts utilized in silico algorithms to
predict epitopes with high MHC binding affinity and then generated
libraries of peptides corresponding to the selected epitopes.21–23,38–41
Although these methods are improving, they are expensive and
limited in their capacity to predict protective T cell epitopes.42,43 In
the mouse malaria models, epitope prediction algorithms have sup-
ported the identification of several pre-erythrocytic antigens that
are targeted by T cell responses induced following immunization
with P. yoelii and P. berghei RAS or SPZ+CQ; however, these antigens
have not demonstrated protective efficacy when tested in challenge
experiments.38–40
We focused on identifying T cell responses specific for pre-erythro-
cytic antigens following immunization with a highly protective
SPZ+CQ vaccine regimen because of the potential for increased
diversity of antigen responses associated with this regimen relative
to RAS.44,45 Using this regimen, we identified a set of 69 pre-eryth-
rocytic stage antigens that were targeted by vaccine-induced CD8+
T cells. Thirteen of these antigens recalled more robust responses
than PyCSP and were expressed in the liver stage of the P. yoelii life
cycle (Table S2).29 The antigen that recalled the most frequent
CD8+ T cell responses, PY02065, is a 173 amino acid conserved
Plasmodium protein with unknown function that is upregulated
throughout the liver stage of the P. yoelii life cycle.29 Since protection
induced by the SPZ+CQ regimen is dependent on CD8+ T cells, we
hypothesized that a subset of the 69 antigen-specific CD8+ T cells
that we identified may contribute to the robust protection observed
with this regimen. We tested this hypothesis by evaluating the protec-
tive efficacy induced by a DNA prime-Ad5 boost regimen expressing
the antigen that recalled the most frequent CD8+ T cells, PY02065.
This robust T cell vaccine regimen was partially protective, inducing
sterile protection (absence of blood-stage infection) in 6 of 14 mice
following P. yoelii sporozoite challenge. This finding strongly suggests
that our antigen discovery system is effective at identifying the targetsherapy: Methods & Clinical Development Vol. 7 December 2017 25
Table 1. P. yoelii Genes that Recalled T Cell Responses >2 SDs Higher than the Mean of the Negative Controls
SPZ+CQ Rank P. yoelii Gene ID CD8+ IFNg+ (%) Size (nt) GenVec ID SPZ+CQ Rank P. yoelii Gene ID CD8+ IFNg+ (%) Size (nt) GenVec ID
1 PY02605 1.74 522 GV0014 36 PY02240 1.30 1,131 GV0011
2 PY02989 1.71 1,292 GV0350 37 PY02076 1.29 1,095 GV0041
3 PY02326 1.64 624 GV0139 38 PY00463 1.29 972 GV0112
4 PY02030 1.62 1,485 GV0054 39 PY01621 1.29 2,958 GV0117
5 PY00629 1.52 2,877 GV0113 40 PY00808 1.28 1,359 GV0114
6 PY07062 1.49 939 GV0129 41 PY05019 1.28 1,134 GV0084
7 PY00361 1.48 1,332 GV0033 42 PY00142 1.28 1,950 GV0130
8 PY04421 1.48 390 GV0402 43 PY06454 1.27 525 GV0030
9 PY05048 1.47 1,008 GV0110 44 PY04001 1.26 444 GV0372
10 PY07825 1.46 726 GV0032 45 PY02435 1.26 408 GV0401
11 PY05748 1.45 5,319 GV0050 46 PY01556 1.26 1,836 GV0135
12 PY04475 1.43 894 GV0066 47 PY03629 1.26 1,509 GV0065
13 PY02148 1.41 972 GV0118 48 PY05566 1.26 1,116 GV0446
14 PY03168 1.39 1,194 CSP 49 PY04605 1.26 645 GV0294
15 PY05088 1.39 630 GV0111 50 PY05369 1.26 1,308 GV0451
16 PY06246 1.38 1,209 GV0104 51 PY01620 1.26 2,151 GV0067
17 PY01731 1.37 708 GV0009 52 PY00082 1.25 1,716 GV0001
18 PY07531 1.36 438 GV0031 53 PY03102 1.25 360 GV0369
19 PY02175 1.35 1,377 GV0119 54 PY04293 1.25 1,086 GV0099
20 PY03289 1.35 894 GV0326 55 PY04306 1.24 633 GV0046
21 PY01848 1.34 744 GV0107 56 PY03138 1.24 1,680 GV0058
22 PY04028 1.34 1,398 GV0049 57 PY00592 1.24 1,410 GV0003
23 PY03601 1.34 1,524 GV0122 58 PY02214 1.24 525 GV0196
24 PY03098 1.34 2,058 GV0121 59 PY02722 1.24 705 GV0015
25 PY01182 1.33 1,716 GV0106 60 PY00920 1.23 1,239 GV0059
26 PY01906 1.33 2,643 GV0108 61 PY03879 1.23 1,875 GV0055
27 PY00858 1.32 1,419 GV0040 62 PY00382 1.22 633 GV0131
28 PY02102 1.32 696 GV0138 63 PY00723 1.21 936 GV0439
29 PY04079 1.31 828 GV0123 64 PY00572 1.21 1,326 GV0002
30 PY00935 1.31 1,506 GV0105 65 PY01758 1.21 825 GV0320
31 PY06529 1.31 1,847 GV0128 66 PY07442 1.21 852 GV0436
32 PY01558 1.31 2,547 GV0116 67 PY03674 1.21 1,686 GV0360
33 PY00196 1.30 738 GV0431 68 PY03081 1.21 3,657 GV0057
34 PY03814 1.30 3,690 GV0048 69 PY03150 1.21 891 GV0092
35 PY01863 1.30 954 GV0137
nt, nucleotide.
Molecular Therapy: Methods & Clinical Developmentof protective T cell responses to malarial infection, although addi-
tional antigens that recalled CD8+ T cells in our screen will need to
be tested to further confirm our hypothesis.
Our malaria vaccine development efforts focus on improving
DNA-Ad5-CA, a first-generation vaccine candidate that induced an
encouraging 27% sterile protection in human volunteers challenged
with controlled human malaria infection (CHMI).40 DNA-Ad5-CA26 Molecular Therapy: Methods & Clinical Development Vol. 7 Decembis a DNA prime-Ad5 boost regimen that expresses two
P. falciparum antigens: PfCSP and apical membrane antigen
1 (PfAMA1). CD8+ T cell responses specific for PfAMA1 were asso-
ciated with protection, and 2 of the 4 protected volunteers had the
highest frequency of CD8+ T cell responses specific for PfCSP. Our
goal is to increase vaccine efficacy to meet the preferred product
characteristic target of 75% efficacy set forth by the World Health
Organization (WHO).46 Since overall efficacy of DNA-Ad5-CA waser 2017
Table 2. Immunization with PY02605 Partially Protects BALB/c Mice from
P. yoelii Sporozoite Challenge
Vaccine Antigen Protected/Total Protection (%) p Valuea
Null 0/14 0 NA
PyCSP 14/14 100 <0.001
PY02605 6/14 43 0.016
PY05837 1/14 7 1
aFisher’s exact test (two-sided) versus null. Alpha < 0.05.
www.moleculartherapy.orglimited by pre-existing immunity to the Ad5 vector,40 we have
selected a highly immunogenic gorilla-based adenovector,
GC46,34,35,47 for advancement and have recently demonstrated supe-
rior immunogenicity and protection with this vector relative to Ad5
in a malaria model.47 In animal models, GC46 performance is similar
to chimpanzee adenovirus type 3,48 and given the excellent safety,
immunogenicity, and efficacy data that have been achieved with the
chimpanzee-based adenovirus vectors in humans,49–54 we are enthu-
siastic about the potential to test GC46 vectors expressing CSP and
AMA-1 in the clinic. Additional improvements in efficacy can be
obtained by increasing the number of antigens in this vaccine
regimen.55,56 In this regard, PF3D7_0932900, the P. falciparum
ortholog of PY02065, and the P. falciparum orthologs of other anti-
gens identified in this work have potential to increase the efficacy of
the DNA-Ad5-CA vaccine candidate.
MATERIALS AND METHODS
Primer Design, Gene Amplification, and Plasmid Cloning
Highly abundant P. yoelii pre-erythrocytic antigens with identifiable
P. falciparum orthologs were selected for inclusion in the Ad-array.
We included genes encoding proteins R130 amino acids in length
because larger proteins have a greater probability of containing
T cell epitopes. The DNA sequences of the selected genes used for
amplification were obtained from the PlasmoDB database.57 All
of the single exon genes were amplified directly from P. yoelii
(17XNL) genomic DNA using a pair of gel purified primers: the for-
ward (fwd) primer contains the Kozak consensus CACC upstream of
the starting codon ATG, the reverse (rev) primer retains the native
stop codon at the end of the oligonucleotide, and both of the primers
were designed to have the same melting temperature (Tm) at 66C.
PCR amplification was performed using high-fidelity platinum Taq
polymerase (Invitrogen, Carlsbad, CA) or Hot Star polymerase
(QIAGEN, Gaithersburg, MD). For multi-exon genes, we amplified
individual exons first, and then assembled individual exons into an
intact gene product using the cDNA synthesis PCR.58 All PCR-ampli-
fied gene products were cloned into a shuttle vector, pCR8/GW/
TOPO (Invitrogen, Carlsbad, CA). The correct orientation of the
clones was confirmed by DNA sequencing using M13 fwd and
M13 rev oligonucleotides. The pAdFlex plasmids pACE1(3511rfC)
E3(10X) and pACE1(t.rfC.MCS)E3(10X) contain the full-length
Ad5 genome with deletions in the E1 and E3 regions. Within the
E1 region, we inserted attB1 and attB2 elements for lambda recombi-
nation and a CMV promoter and poly(A) sequences for antigenMolecular Texpression. The genes in the shuttle vector were moved into these
destination gateway-converted adeno plasmids with high efficiency
using the Gateway LR reaction59 (Invitrogen, Carlsbad, CA), in
96-well plate format to generate an array of pAdFlex plasmids
expressing pre-erythrocytic genes from P. yoelii (pAdgPy1-360).
Ad-Array Viral Vector Construction
The Ad-array is an array of adenovirus vectors expressing P. yoelii
antigen genes constructed from an array of pAdFlex plasmids. Briefly,
the recombinant Ad5 genomes containing an antigen gene expression
cassette in the E1 region were liberated from pAdFlex plasmids by
digestion with Pac I or I-CeuI restriction endonuclease, which cleaves
adjacent to the inverted terminal repeats (ITRs) of the Ad5 genome.
This vector DNA (60 ng) was transfected into monolayer 293 cells
seeded at 70,000 cells per well in 96-well plates using 0.7 mL polyfect
transfection reagent (QIAGEN, Gaithersburg, MD). Three days later,
transfected cells were frozen and thawed three times to lyse the cells,
releasing infectious recombinant virus, and 18 mL of these lysates
was used to infect fresh 293 cells in another 96-well plate. Cell lysates
were serially passaged in this manner every 3 days until CPE was
observed. The identity of the adenovector was determined
using primers Ad5s278 (CGCGGGAAAACTGAATAAGA) and
Ad5a3598 (GCTGCTGCAAAACAGATACA) as indicated in Fig-
ure 2B. Vector yields were determined by using the ffu assay60 on a
subset of approximately 10% of the array to ensure that sufficient
quantities of vector were being produced.
Production of Adenovirus Vectors for Protection Studies in Mice
To generate sufficient vector for mouse protection experiments, resid-
ual CPE lysates were expanded in four 10-cm plates and the cell
lysates were harvested 3 days later. The expanded cell lysates were
analyzed to determine infectious vector particle concentration, were
analyzed by PCR to ensure vector genomic integrity, and were used
to seed a production run in suspension 293-ORF6 cells in shaker
flasks using serum-free media. Three days after infection, the recom-
binant vectors were released from infected cells by three cycles of
freeze-thawing, treated with benzonase (EMD Millipore, Billerica,
MA), purified by banding on two successive CsCl gradients, dialyzed
into final formulation buffer and stored at80C. Physical PUs were
determined by absorbance at 260 nm following disruption of the
capsid with SDS.
Mice, Parasites, and Cells
The study protocols were reviewed and approved by the Walter Reed
Army Institute of Research/Naval Medical Research Center (NMRC)
and GenVec Institutional Animal Care and Use Committees in
compliance with all applicable federal regulations governing the pro-
tection of animals in research. Female (6- to 8-week-old) BALB/c
mice were purchased from Harlan Laboratories (http://www.envigo.
com) or Charles River Laboratories (Wilmington, MA). CD1 outbred
mice (5–6 weeks old) were purchased from Charles River Labora-
tories (Wilmington, MA). P. yoelii (17XNL non-lethal strain,
clone 1.1) parasites were maintained by alternating passage in Anoph-
eles stephensi mosquitoes and female CD1 mice. HEK293 cells, aherapy: Methods & Clinical Development Vol. 7 December 2017 27
Figure 6. The P. falciparum Ortholog of PY02605,
PF3D7_0932900, Is Immunogenic in BALB/c Mice
Mice were immunized with 1  109 PU of
GC46.PF3D7_0932900 or a control adenovector that
does not express a transgene, GC46.Null. Three weeks
post-immunization, mice were euthanized and
PF3D7_0932900-specific CD8+ (A) and CD4+ (B) T cell
responses were measured by ICS and flow cytometry
following 4-hr stimulation using pooled overlapping
15-mer peptides.
Molecular Therapy: Methods & Clinical Developmenthuman embryonic kidney cell line transformed by sheared adeno-
virus type 5 DNA, were obtained from the American Type Culture
Collection (Rockville, MD, USA) and maintained in DMEM supple-
mented with 10% calf serum. The A20.2J (ATCC clone HB-98) B cell
line derived from BALB/c mice, which expresses both class I and class
II MHC genes,61 was purchased from ATCC and maintained in
RPMI-1640 medium supplemented with 20% fetal bovine serum
(FBS) and 1% glutamine.
Immunization Regimens
RAS were generated by exposing salivary gland P. yoelii sporozoites
to 10,000 rads. To obtain splenocytes for testing recall responses
to PyCSP, female BALB/c mice were immunized, via tail vein injec-
tion, with three doses of RAS (10,000, 5,000, and 5,000) at 3-week
intervals.
For SPZ+CQ immunizations, female BALB/c mice were immunized
with two administrations (1 month apart) of live infectious P. yoelii
sporozoites. Various doses of sporozoites were tested (group
1 = 20,000, group 2 = 2,000, group 3 = 200, group 4 = 0). Infected
mice received a 0.1mL intraperitoneal injection of a solution
of chloroquine hydrochloride (Sigma-Aldrich, St. Louis, MO)
8 mg/mL diluted in PBS, to kill newly emerging blood-stage parasites,
starting on the same day as sporozoite immunizations and continuing
for 10 consecutive days following each sporozoite immunization. For
both SPZ+CQ and RAS immunizations, most of these mice were
euthanized 2 weeks after the last dose to obtain splenocytes for
T cell analysis. However, a subset of the mice was infected with
P. yoelii sporozoites to insure that 100% sterile protection had been
achieved, as described below.
For plasmid DNA immunizations, BALB/c mice were immunized
with 100 mg DNA vector, pPyCSP, in a 0.1 mL volume by intramus-
cular immunization as described previously.62 Two weeks later,
mice were euthanized to obtain splenocytes for analysis. For
DNA-Ad5 immunizations, BALB/c mice were immunized with
100 mg of DNA vector, pcDNA3.2-Dest (Invitrogen, Carlsbad,
CA) in a 0.1 mL volume by intramuscular immunization. Six weeks
later, these mice were boosted with 1  1010 PU of Ad5 vector in
a 0.1 mL volume. For both DNA and Ad5 administrations, we
performed bilateral injections into the tibialis anterior muscles
with a 0.3-mL syringe and a 29G1/2 needle (Becton Dickinson
Co., Franklin Lakes, NJ).28 Molecular Therapy: Methods & Clinical Development Vol. 7 DecembFor GC46.PF3D7_0932900 immunizations, BALB/c mice were
immunized with a single dose of 1 109 PU ofGC46.PF3D7_0932900
by the intramuscular route with a 1-mL syringe and a 30G needle
(Becton Dickinson Co., Franklin Lakes, NJ). At 21 days post-immuni-
zation, mice were euthanized for splenocyte harvest and assessment of
immune responses by ICS and flow cytometry.
Protection Studies
Protection studies were performed as previously described.55 Mice
were challenged intravenously in the tail vein with 200 P. yoelii
sporozoites using a 1-mL syringe and 26G1/2 needle. Sporozoites
were hand dissected from infected mosquito salivary glands63 and
diluted for challenge in M199 medium containing 5% normal mouse
serum (Gemini Bio-Products, West Sacramento, CA). The develop-
ment of parasitemia was monitored over the next 2 weeks by micro-
scopic examination of Giemsa-stained blood smears. Mice were
considered protected if no parasites were observed in any sample at
day 6, day 9, or day 14 post-challenge.
Infection of A20 Cells
A20.J2 cells (ATCC,Manassas, VA), also referred to as A20 cells, are a
B cell line derived from BALB/c mice that expresses both class I and
class II major histocompatability complex genes. A20 cells were
grown in 15 mL fresh RPMI-1640 media plus 20% FBS and 1%
L-glutamine in 25-mL T-flasks. The T-flasks were kept upright and
incubated at 37C in a 5% CO2 incubator. When the cells reached a
density of 1.21.8  106 cells/mL, they were used to seed 12-well
plates at a density of 5.0  105 cells/well. The following day, the cells
were infected with AdGFP, an adenovirus vector that expresses GFP,
for 2 hr in a volume of 200 mL. After infection, cells were washed with
PBS, overlaid with 1 mL fresh media, and incubated at 37C and 5%
CO2 for 48 hr. The percentage of the GFP
+ cells was analyzed by flow
cytometry. For the array screening, 6 105 A20.2J cells were infected
with 150 mL CPE lysate from each of the Ad-array vectors in a volume
of 350 mL in 24-well plates for 2 hr. After infection, 0.25 mL fresh
media were added to each well and the infected cells were incubated
at 37C and 5% CO2 for 24 hr before plating in the stimulations
described below.
ICS and Flow Cytometry Analysis
Stimulation by Ad5-Infected A20 Cells
Splenocytes harvested from SPZ+CQ or RAS-immunized animals
were stimulated by co-culture with infected/irradiated A20 cells iner 2017
www.moleculartherapy.org96-well plates. Spleens were gently crushed using the flat end of a 3-cc
or 10-cc syringe plunger, and the cell suspension was passed through
a 70-mm filter. The splenocytes were washed with ice-cold 2% FBS/
10 mM HEPES/1 Hank’s balanced salt solution (HBSS), resus-
pended in RPMI, counted, diluted to 1  107 cells/mL in RPMI
medium, and plated at 1  106 cells/well in 96-well plates. At 24 hr
after infection, A20 cells were irradiated in a Pantak X-Rad 320 irra-
diator at 16,666 rads. After irradiation, the viable cell concentration
was adjusted to 1.5  106 cells per mL and 1.5  105 infected cells
were transferred to each well of U-bottom 96-well plates preloaded
with 1  106 splenocytes from vaccinated or naive mice, in triplicate,
and incubated for 5 hr at 37C. BD Golgi Plug (BD Bioscience, San
Jose, CA) was added 1 hr into the incubation to block cytokine release.
Cells were centrifuged at 1,200 rpm for 5 min, the supernatant was
flicked, and the cell pellets were resuspended by gentle vortexing.
Live and dead cells were first stained with LIVE/DEAD Fixable
Aqua stain kit (BD Biosciences, San Diego, CA), then the cells were
blocked with FC Block (BD Biosciences, San Diego, CA). After block-
ing, cell surface markers were stained with the following antibodies
(fluorochromes): CD4-eFluor-450 (clone RM4-5; eBioscience, San
Diego, CA) and CD8a-PerCP-Cy5.5 (clone 53-6.7; BD Biosciences,
San Diego, CA). Following fixation/permeabilization steps, the sam-
ples were stained intracellularly with the following antibodies (fluoro-
chromes): IFN-g-PE (clone XMG 1.2), TNF-a APC (clone MP6
XT22), and IL-2-Alexa488 (clone JES6-5H4) (BD Biosciences, San
Diego, CA). The frequency of CD4+ and CD8+ T cells, as well as
antigen-specific IFNg, TNF-a, and IL-2 intracellular cytokine-posi-
tive T cells was determined in an 8-color upgraded FACSCalibur
(Becton Dickinson Immunocytometry Systems, San Jose, CA) with
a 96-well Automated Micro-sampling System (AMS) (Cytek,
Fremont, CA). Data were analyzed using FloJo software (Treestar,
Inc., Ashland, OR).
ICS Flow Cytometry Analysis
Stimulation by PF3D7_0932900 Peptide Pools
Splenocytes from GC46.PF3D7_0932900 immunized mice were har-
vest and plated at 2  106 cells per well in a 96-well v-bottom plate.
Cells were stimulated for 4 hr in the presence of 20 mg/mL brefeldin
A (Sigma-Aldrich, St. Louis, MO) with either 15-mer peptides for the
PF3D7_0932900 antigen at 2 mg/mL, overlapping by 10 amino acids
(Mimotopes, Victoria, Australia), or 1% DMSO as a negative control.
Subsequently, cells were stained with the LIVE/DEAD Fixable Blue
Dead Cell Stain Kit, for UV excitation (Invitrogen, Grand Island,
NY), surface stained with CD14 phycoerythrin (PE) (clone Sa14-2;
Life Technologies, Grand Island, NY), CD19 Brilliant Violet 650
(clone 6D5; Biolegend, San Diego, CA), CD3 Alexa 700 (clone
17A2; Biolegend, San Diego, CA), CCR7 PerCPCy5.5 (clone 4B12;
eBioscience, San Diego, CA), CD44 Pacific Blue (clone IM7;
Biolegend, San Diego, CA), and CD62L Brilliant Violet 786 (clone
MEL-14; BD Biosciences, San Diego, CA) and permeabilized using
Cytofix/Cytoperm reagent (BD Biosciences, San Diego, CA). Cells
were then intracellularly stained with CD4 Brilliant Violet 605 (clone
RM4-5; Biolegend, San Diego, CA), together with CD8Horizon V500
(clone 53-6.7), TNF Cy7PE (clone MP6-XT22), IFNg allophyco-Molecular Tcyanin (clone XMG1.2), and IL-2 FITC (clone JES6-5H4; BD
Biosciences, San Diego, CA). Samples were acquired using an LSR
Fortessa (Becton Dickinson Immunocytometry Systems, San Jose,
CA) and data were analyzed using FlowJo version 9.4.11 (TreeStar
Inc., Ashland, OR). To identify antigen-specific responses, cells
were gated on forward scatter (threshold), exclusion of aggregates,
and subsequently to include singlets, viable cells, CD14, CD3+,
CD19, CD3+, lymphocytes, and either CD4+ or CD8+ populations.
ELISpot Assay
RAS splenocytes were stimulated in vitro with Ad5-transduced or
PyCSP peptide-pulsed APCs and the number of P. yoelii antigen-spe-
cific IFNg-secreting spot-forming cells was evaluated after a 36-hr
culture period. Splenocytes were tested at 400,000, 200,000, and
100,000 per well, while APCs were tested at 100,000 per well. Assays
were performed in triplicate and the number of IFNg-secreting cells,
recognized as spot-forming cells (SFCs), was counted using an auto-
mated ELISpot Reader manufactured by AutoImmun Diagnostika
(AID) GmbH (Strassberg, Germany). Data were presented as the
number of IFNg-secreting SFCs per million spleen cells.
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